HOME >> MEDICINE >> NEWS
Combination therapy does not appear to benefit cardiac patients before heart catheter procedure

Patients with acute myocardial infarction (MI - heart attack) who are referred for percutaneous coronary intervention (such as angioplasty and stent placement in the coronary artery) do not have a reduction in the amount of damaged heart tissue when administered two drugs compared with a single drug to restore blood flow, according to a study in the February 25 issue of The Journal of the American Medical Association (JAMA).

According to background information in the article, "In hospitals with catheterization facilities, primary percutaneous coronary interventions (PCIs) are better then thrombolysis (drug therapy used to dissolve blood clots) in patients with ST-segment elevation acute MI. Specifically designed randomized trials have also shown that patients with acute MI presenting at hospitals without catheterization facilities benefit more from PCI performed after transfer to centers with catheterization laboratories than from on-site thombolysis."

Adnan Kastrati, M.D., from Deutsches Hezzentrum, Technische Universitat, Munich, Germany, and colleagues from the Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators, assessed whether early administration of the combination of the drugs reteplase plus abciximab produces better reduction of infarct size compared with abciximab alone in patients with acute MI referred for PCI. The study, conducted from May 3, 2001 through June 2, 2003, included 253 patients who were admitted to 13 community hospitals without catheterization facilities (n=186) and to 5 hospitals with catheterization facilities (n=67), within 12 hours of symptoms of an acute MI. Patients randomly received either the combination of reteplase and abciximab (n=125) or abciximab (n=128) alone. All patients were then transferred for PCI. Infarct size was later determined by imaging from a single-photon emission computed tomography (SPECT).

"The final infarct size of the left ventricle, the primary en
'"/>

Contact: Adnan Kastrati, M.D.
kastrati@dhm.mhn.de
JAMA and Archives Journals
24-Feb-2004


Page: 1 2

Related medicine news :

1. Combination treatment helps thyroid cancer patients live longer
2. Combination therapy, not medication alone, most effective for treating children with OCD
3. Combination of erection pill and testosterone gel may benefit men who fail treatment with pill alone
4. Combination therapy w/ ACTOS (pioglitazone HCI) shown to improve components of diabetic dyslipidemia
5. Combination PET/CT should be used to determine stage of non-small cell lung cancer
6. Combination of toxin and poison may be novel treatment for leukemia
7. Combination drug therapy could substantially improve symptoms of rheumatoid arthritis
8. Combination drug therapy offers hope for malaria treatment
9. Combination therapy significantly delays progression of benign prostatic hyperplasia
10. Combination, order of anti-HIV drugs make a difference in first-time recipients
11. Combination of HIV/malaria increases complications during pregnancy

Post Your Comments:
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in national ... Powder Cancer Lawsuit Center website. Just as the previous version did, the new website ... timely lawsuit updates and ovarian cancer warning information. The site is routinely updated with ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... great for documenting memories. , Almost every smartphone has an incredibly powerful camera built ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently running ... to those of celebrities will have the opportunity to get 10% discount on orders ... that people do not have to use coupon codes or remember redemption codes. ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is ... is now the 19th sweetFrog store located in the Lone Star State. The premium ... growing companies in 2014. , The store, which opened July 1 at Duke’s Travel ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... retrofit project at the University of Minnesota, they knew it would save the ... also be an award-winning choice: the total energy savings after installation was an ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2
(Date:7/2/2015)... ATLANTA , July 2, 2015 Legal-Bay ... U.S. District Judge Joseph Goodwin in the ... (VA) consolidated 26 transvaginal mesh cases against Ethicon for ... nd . The cases for the 26 women include ... by a device made my Johnson & Johnson,s Ethicon ...
(Date:7/1/2015)... SCHAUMBURG, Ill. , July 1, 2015 /PRNewswire-USNewswire/ ... a nationwide group of state and regional professional ... national survey of rheumatologists that explored perceptions of ... drugs on patients. Biosimilars are ... to biologic medicines. They are notably different from ...
(Date:7/1/2015)... 1, 2015   Cochlear Limited (ASX: ... announced today the US Food and Drug Administration ... with Slim Straight Electrode (CI522). Built on over ... collaboration with the world,s leading surgeons, the Profile ... to provide the most discreet appearance for both ...
Breaking Medicine Technology:Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 3
Cached News: